SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-20-224092
Filing Date
2020-08-19
Accepted
2020-08-19 06:13:30
Documents
14
Effectiveness Date
2020-08-19

Document Format Files

Seq Description Document Type Size
1 DEFA14A d37632ddefa14a.htm DEFA14A 79332
2 GRAPHIC g37632g03t60.jpg GRAPHIC 4797
3 GRAPHIC g37632g07d19.jpg GRAPHIC 2275
4 GRAPHIC g37632g20w29.jpg GRAPHIC 6335
5 GRAPHIC g37632g26t22.jpg GRAPHIC 15278
6 GRAPHIC g37632g27c63.jpg GRAPHIC 2844
7 GRAPHIC g37632g28s01.jpg GRAPHIC 2072
8 GRAPHIC g37632g31n65.jpg GRAPHIC 34466
9 GRAPHIC g37632g43f89.jpg GRAPHIC 12138
10 GRAPHIC g37632g45u30.jpg GRAPHIC 33208
11 GRAPHIC g37632g49d64.jpg GRAPHIC 3577
12 GRAPHIC g37632g63x79.jpg GRAPHIC 3607
13 GRAPHIC g37632g77n79.jpg GRAPHIC 3583
14 GRAPHIC g37632g98w46.jpg GRAPHIC 2060
  Complete submission text file 0001193125-20-224092.txt   248300
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36510 | Film No.: 201115284
SIC: 2834 Pharmaceutical Preparations